Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

PLX Stock: Why Protalix BioTherapeutics Is Plunging 40% Today

By Robert Lakin, InvestorPlace Contributor

An update from Protalix BioTherapeutics shows how a disappointing FDA decision can roil a biotech name like PLX stock.

NVAX Stock: The Big Covid-19 Vaccine News Lifting Novavax Today

By Robert Lakin, InvestorPlace Contributor

NVAX stock looks to gain for a third straight day as Biden eyes using the Novavax Covid-19 shot to help with international aid.

FTCI Stock IPO: What to Know as FTC Solar Preps to Come Public

By Robert Lakin, InvestorPlace Contributor

A seasoned team of solar industry veterans is behind FTC Solar as the panel tracking equipment and software maker has its IPO. FTCI stock will start trading on Wednesday.

NSPR Stock: What You Should Know About InspireMD Today

By Robert Lakin, InvestorPlace Contributor

InspireMD has vastly reduced the number of its shares trading ahead of a likely move to a Nasdaq listed. Conversion of NSPR stock warrants and preferred shares will be more difficult now.

AXSM Stock: The Big FDA News Giving Axsome Therapeutics a Boost

By Robert Lakin, InvestorPlace Contributor

AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now.

Load More